Suppr超能文献

用于幽门螺杆菌相关性胃炎的植物提取物或化合物:动物实验中其抗幽门螺杆菌活性和抗炎作用的系统评价

Plant-derived extracts or compounds for Helicobacter-associated gastritis: a systematic review of their anti-Helicobacter activity and anti-inflammatory effect in animal experiments.

作者信息

Chen Danni, Wang Wenlai, Chen Xiangyun, Liang Ning, Li Jiawang, Ding Wei, Zhang Hongrui, Yang Zhen, Zhao Hongxia, Liu Zhenhong

机构信息

College of Traditional Chinese Medicine, Beijing University of Chinese Medicine, No. 11 Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.

Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, No. 16 Nanxiaojie, Dongzhimen Nei, Dongcheng District, Beijing, 100700, China.

出版信息

Chin Med. 2025 Apr 22;20(1):53. doi: 10.1186/s13020-025-01093-2.

Abstract

BACKGROUND

Helicobacter infection, which is the leading cause of gastritis and stomach cancer, has become common worldwide. Almost all Helicobacter-infected patients have chronic active gastritis, also known as Helicobacter-associated gastritis (HAG). However, the eradication rate of Helicobacter is decreasing due to the poor efficacy of current medications, which causes infection to recur, inflammation to persist, and stomach cancer to develop. Natural components have robust antibacterial activity and anti-inflammatory capacity, as confirmed by many studies of alternative natural medicines.

PURPOSE

This article aimed to conduct a comprehensive search and meta-analysis to evaluate the efficacy of anti-Helicobacter and anti-inflammatory activities of plant-derived extracts or compounds that can treat HAG in animal experiments. We intended to provide detailed preclinical-research foundation including plant and compound information, as well as the mechanisms by which these plant-derived substances inhibit the progression of Helicobacter infection, gastritis and neoplasms for future study.

METHODS

The systematic review is aligned with the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, and the protocol was registered in PROSPERO (CRD42024527889). An extensive search was performed across multiple databases, including PubMed, Scopus, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal database (VIP), the Wanfang database, and the China biomedical literature service system (SinoMed), up until November 2023. Meta-analysis on Review Manager software (RevMan 5.4) estimating anti-Helicobacter and anti-inflammatory activity was performed. We used the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk of bias tool to evaluate the risk of bias of each study included.

RESULTS

Our study encompassed 61 researches, comprised 36 extracts and 37 compounds improving HAG by inhibiting Helicobacter infection, the inflammatory response, oxidative stress, and regulating apoptosis and proliferation. Sixteen families especially Asteraceae, Fabaceae and Rosaceae and nine classes including Terpenoids, Alkaloids, Phenols, and Flavonoids may be promising directions for valuable new drugs. The Meta-analyse demonstrated the plant-base substance treatments possess significant anti-Helicobacter and anti-inflammation activity comparing to control groups. The included plants and compounds confirmed that signaling pathways NF-κB, JAK2/STAT3, MAPK, TLR4/MyD88, PI3K/AKT, NLRP3/Caspase-1 and NRF2/HO-1 play a key role in the progression of HAG.

CONCLUSION

Plant-derived extracts or compounds actively improve HAG by modulating relevant mechanisms and signaling pathways, particularly through the anti-Helicobacter and inflammatory regulation ways. Further researches to apply these treatments in humans are needed, which will provide direction for the future development of therapeutic drugs to increase eradication rate and alleviate gastritis.

摘要

背景

幽门螺杆菌感染是胃炎和胃癌的主要病因,在全球范围内已变得十分普遍。几乎所有感染幽门螺杆菌的患者都患有慢性活动性胃炎,也称为幽门螺杆菌相关性胃炎(HAG)。然而,由于目前药物疗效不佳,幽门螺杆菌的根除率正在下降,这导致感染复发、炎症持续以及胃癌发生。许多替代天然药物的研究证实,天然成分具有强大的抗菌活性和抗炎能力。

目的

本文旨在进行全面的文献检索和荟萃分析,以评估植物提取物或化合物在动物实验中治疗HAG的抗幽门螺杆菌和抗炎活性。我们旨在提供详细的临床前研究基础,包括植物和化合物信息,以及这些植物来源物质抑制幽门螺杆菌感染、胃炎和肿瘤进展的机制,以供未来研究参考。

方法

本系统评价遵循系统评价和荟萃分析的首选报告项目(PRISMA)声明中概述的指南,研究方案已在国际前瞻性系统评价注册库(PROSPERO,注册号:CRD42024527889)中注册。截至2023年11月,我们在多个数据库中进行了广泛检索,包括PubMed、Scopus、科学引文索引(Web of Science)、Embase、中国知网(CNKI)、维普中文科技期刊数据库(VIP)、万方数据库和中国生物医学文献服务系统(SinoMed)。使用Review Manager软件(RevMan 5.4)进行荟萃分析,以评估抗幽门螺杆菌和抗炎活性。我们使用实验动物系统评价中心(SYRCLE)偏倚风险工具来评估纳入的每项研究的偏倚风险。

结果

我们的研究涵盖61项研究,包括36种提取物和37种化合物,它们通过抑制幽门螺杆菌感染、炎症反应、氧化应激以及调节细胞凋亡和增殖来改善HAG。16个科,特别是菊科、豆科和蔷薇科,以及9类化合物,包括萜类、生物碱、酚类和黄酮类,可能是有价值的新药的有前景的研发方向。荟萃分析表明,与对照组相比,植物源性物质治疗具有显著的抗幽门螺杆菌和抗炎活性。纳入的植物和化合物证实,核因子κB(NF-κB)、Janus激酶2/信号转导子和转录激活子3(JAK2/STAT3)、丝裂原活化蛋白激酶(MAPK)、Toll样受体4/髓样分化因子88(TLR4/MyD88)、磷脂酰肌醇-3激酶/蛋白激酶B(PI3K/AKT)、NOD样受体蛋白3/半胱天冬酶-1(NLRP3/Caspase-1)和核因子E2相关因子2/血红素加氧酶-1(NRF2/HO-1)信号通路在HAG的进展中起关键作用。

结论

植物提取物或化合物通过调节相关机制和信号通路,特别是通过抗幽门螺杆菌和炎症调节方式,积极改善HAG。需要进一步研究将这些治疗方法应用于人类,这将为未来治疗药物的开发提供方向,以提高根除率并缓解胃炎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6545/12013188/3143fed1873e/13020_2025_1093_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验